Sign in
Taking peoplePhase 4

Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).

Key facts

Who runs it
Ole Hyldegaard
Where
Belgium and Norway2 sites in 2 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 4
People taking part
1,480 people, planned
Started
4 Apr 2026
Expected to end
30 Jun 2033
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hyperbaric oxygen treatment
  • Standard of Care (Investigator Choice)
Record updated
4 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults (age ≥18 years)
  • Surgical confirmed NSTI (defined by perioperative tissue characteristics observed by the surgeon. The diagnosis is based on sign as necrotic or deliquescent soft tissue with widespread undermining of the surrounding tissue)

Who cannot take part

  • Previously randomized into the HOT-NSTI trial
  • Allergy against study drug
  • Contraindications for HBO2 treatment according to local protocol (e.g., undrained pneumothorax)
  • Confirmed pregnancy
  • Referred to palliative care
  • Known objection by the patient to participate in the trial

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Necrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades. The standard of care in NSTI is multidisciplinary and includes surgery, intensive care, and broad-spectrum antibiotics. Hyperbaric oxygen (HBO2) treatment is an adjunctive treatment potentially improving survival, but is not standard of care in many centres, presumably as no evidence of its benefit from randomized clinical trial exists.

Read full original descriptionShow less

The primary objective of this trial, HOT-NSTI, is to investigate the effect of adjunctive HBO2 treatment on 30-day all-cause mortality in patients with NSTI.

The 2 groups in the trial

  • Standard of careExisting treatment, for comparison

    standard of care (e.g. intensive care, surgery, antibiotics)

    Treatment: Standard of Care (Investigator Choice)

  • Standard of care + hyperbaric oxygen treatmentTreatment being tested

    standard of care (e.g. intensive care, surgery, antibiotics) + hyperbaric oxygen treatment

    Treatment: Hyperbaric oxygen treatment and Standard of Care (Investigator Choice)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial)
Record updated
4 September 2026